HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public Device Companies Take a Hit, But Still Stand

Executive Summary

The health care sector has traditionally provided a haven for investors seeking the security of an industry blessed with a rock solid customer base. After all, consumer confidence plays a limited role in the bulk of health care decisions. But IN VIVO's survey of 62 publicly traded medical device companies shows the sector has taken a beating along with the rest of Wall Street. Surprisingly, potentially vulnerable sectors, like orthopedics and big ticket equipment, have shown a remarkable resiliency.

You may also be interested in...



AF Ablation: The Pulse of Innovation

The atrial fibrillation market has attracted the attention of a large number of established and emerging cardiovascular device companies over the past several years, all hoping to cash in on the huge demand for a simple, safe, and effective therapy that can permanently cure this common, and often debilitating, heart arrhythmia. Most of the research to date has focused on energy-based methods both surgical and percutaneous - to destroy aberrant electrical triggers in the heart that are believed to initiate and perpetuate AF. But no one has yet received FDA approval for a catheter-based ablation tool, a milestone that is widely recognized as key to full penetration of this market. To be sure, they have come close. But obtaining an FDA indication for the more complex AF ablation procedure has proven a much more difficult goal.

Thermage/Reliant: Evidence of Tightening in the Aesthetics Market

The aesthetics industry is becoming increasingly competitive and there are very few intellectual property barriers to entry; as soon as one company develops a new wrinkle-reducing device, it's not long before others come up with something that sounds similar. Sales and marketing account for the biggest costs of medical aesthetic companies, and because a number of the newer one-product companies now find themselves bumping into their competitors in physicians' offices and at trade shows, consolidation in the industry appears to be in order. In this challenging environment, the recent merger of skin tightening company Thermage with skin resurfacing firm Reliant is designed to create a stronger competitor.

TomoTherapy: Niche Player or Not?

Radiation oncology is a very attractive market indeed. It's a $3 billion-plus capital equipment market predicted to experience a compound annual growth rate of 10 to 15% in the next several years, with the image-guided segment expected to grow at a 35% rate. Approximately 30% of the market is up for grabs over the next three years, as institutions replace old and obsolete equipment. Can small company TomoTherapy sustain the lead it has gained with a new image-guided system that increases the precision of cancer targeting and spares normal tissues, once entrenched multi-billion dollar radiation oncology companies begin to offer aggressive competition?

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel